Case number 1:19-cv-02021
Novartis Pharmaceuticals Corporation v. Alembic Pharmaceuticals Limited et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Mar 6, 2024 | 255 | ORDER of USCA for the Federal Circuit as to 246 Notice of Appeal (Federal Circuit), filed by Novartis Pharmaceuticals Corporation. Decision of USCA: Appeal No. 2023-2260 is deconsolidated from Appeal Nos. 2023-2218, 2023-2219, 2023-2220, and 2023-2221, and Appeal No. 2023-2260 is dismissed. Each side shall bear its own costs regarding Appeal No. 2023-2260. The stay in Appeal Nos. 2023-2218, 2023-2219, 2023-2220, and 2023-2221 is lifted. The Clerk of Court shall transmit a copy of this order to the merits panel assigned to Appeal Nos. 2023-2218, 2023-2219, 2023-2220, and 2023-2221. (nms) (Entered: 03/06/2024) (3) |
| Feb 22, 2024 | 254 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,101,659; 8,796,331; 8,877,938; 9,388,134. (Attachments: # 1 Consent Judgment and Order)(nms) (Entered: 02/22/2024) (0) |
| Feb 21, 2024 | 253 | REDACTED VERSION of 250 Proposed Consent Judgment, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 2/22/2024 (nms). (Entered: 02/21/2024) (6) |
| Feb 13, 2024 | 252 | STIPULATION and Proposed Order to Extend Time to file public version of the [Proposed] Consent Judgment and Order of Injunction to February 20, 2024 - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 2/13/2024 (nms). (Entered: 02/13/2024) (3) |
| Feb 7, 2024 | 251 | [SEALED] Consent Judgment and Order of Injunction between Plaintiff and Defendants Alembic Global Holding SA, Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc.. Signed by Judge Richard G. Andrews on 2/7/2024.*This order has been emailed to local counsel. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-02021-RGA, 1:20-cv-00074-RGA, 1:22-cv-01395-RGA(nms) (Entered: 02/07/2024) (0) |
| Feb 6, 2024 | 250 | [SEALED] Proposed Consent Judgment and Order of Injunction, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 2/6/2024 (nms). (Entered: 02/06/2024) (0) |
| Aug 14, 2023 | 249 | MOTION for Pro Hac Vice Appearance of Attorney Deanne E. Maynard of Morrison & Forester LLP - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 08/14/2023) (4) |
| Aug 11, 2023 | 248 | NOTICE of Lodging of Trial Demonstrative Exhibits by Novartis Pharmaceuticals Corporation (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C)(Silver, Daniel) (Entered: 08/11/2023) (0) |
| Aug 1, 2023 | 247 | NOTICE of Docketing Record on Appeal from USCA for the Federal Circuit re 246 Notice of Appeal (Federal Circuit), filed by Novartis Pharmaceuticals Corporation. USCA Case Number 2023-2220. (nms) (Entered: 08/01/2023) (4) |
| Jul 24, 2023 | 246 | NOTICE OF APPEAL to the Federal Circuit of 245 Judgment . Appeal filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 07/24/2023) (3) |
| Jul 21, 2023 | 245 | FINAL JUDGMENT Regarding U.S. Patent No. 8,101,659 (see Judgment for further details). Signed by Judge Richard G. Andrews on 7/21/2023. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA, 1:19-cv-02021-RGA, 1:19-cv-02053-RGA(nms) (Entered: 07/21/2023) (5) |
| Jul 20, 2023 | 242 | PROPOSED Final Judgment, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 7/21/2023 (nms). (Entered: 07/20/2023) (5) |
| Jul 20, 2023 | 243 | REDACTED VERSION of 240 Proposed Consent Judgment, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 7/21/2023 (nms). (Entered: 07/20/2023) (4) |
| Jul 20, 2023 | 244 | REDACTED VERSION of 241 Consent Judgment, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 7/21/2023 (nms). (Entered: 07/20/2023) (4) |
| Jul 13, 2023 | 240 | [SEALED] Proposed Consent Judgment and Order of Injunction betwen Plaintiff and Defendants Macleods Pharmaceuticals Ltd. and Macleods Pharma USA, Inc., by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 7/13/2023 (nms). (Entered: 07/13/2023) (0) |
| Jul 13, 2023 | 241 | [SEALED] Consent Judgement and Order of Injunction between Plaintiff and Defendants Macleods Pharmaceuticals Ltd. and Macleods Pharma USA, Inc.. Signed by Judge Richard G. Andrews on 7/13/2023.This order has been emailed to local counsel. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-02021-RGA, 1:21-cv-01330-RGA(nms) (Entered: 07/13/2023) (0) |
| Jul 7, 2023 | 239 | TRIAL OPINION (Regarding the '659 Patent): For the foregoing reasons, I find the asserted claims of the '659 Patent invalid for lack of written description. The parties shall submit a final judgment consistent with this memorandum opinion within one week (see Opinion for further details). Signed by Judge Richard G. Andrews on 7/7/2023. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA, 1:19-cv-02021-RGA, 1:19-cv-02053-RGA(nms) Modified on 7/11/2023 (nms). (Entered: 07/07/2023) (46) |
| Jun 29, 2023 | 238 | MOTION for Pro Hac Vice Appearance of Attorney Melinda R. Roberts - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certification for Melinda R. Roberts)(Silver, Daniel) (Entered: 06/29/2023) (Main Document) (4) |
| Jun 29, 2023 | 238 | MOTION for Pro Hac Vice Appearance of Attorney Melinda R. Roberts - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certification for Melinda R. Roberts)(Silver, Daniel) (Entered: 06/29/2023) (Certification for Melinda R. Roberts) (1) |
| Apr 20, 2023 | 237 | NOTICE of Withdrawal of Appearance of Daniel J. McBride, Esq. of Abrams & Bayliss LLP, as counsel for defendants Macleods Pharmaceuticals Ltd. and Macleods Pharma USA, Inc. by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd. (Seaman, John) (Entered: 04/20/2023) (1) |
| Mar 22, 2023 | 236 | NOTICE of Change of Address by Alexandra M. Joyce (Joyce, Alexandra) (Entered: 03/22/2023) (5) |
| Jan 24, 2023 | 234 | Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., regarding hyperlinked post-trial briefs for the 659 patent. (Silver, Daniel) Modified on 1/25/2023 (nms). (Entered: 01/24/2023) (1) |
| Jan 24, 2023 | 235 | Letter to the Honorable Richard G. Andrews, from Stamatios Stamoulis, regarding hyperlinked post-trial briefs for the 659 patent. (Stamoulis, Stamatios) Modified on 1/25/2023 (nms). (Entered: 01/24/2023) (1) |
| Jan 13, 2023 | 233 | POST-Trial Reply Brief re Invalidity, by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Gattuso, Dominick) Modified on 1/13/2023 (nms). (Entered: 01/13/2023) (26) |
| Dec 16, 2022 | 231 | POST-TRIAL Answering Brief on the Validity of the '659 Patent, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 12/18/2022 (nms). (Entered: 12/16/2022) (30) |
| Dec 16, 2022 | 232 | Proposed Findings of Fact by Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 12/16/2022) (30) |
| Dec 15, 2022 | 230 | NOTICE of Lodging of Defendants' Trial Demonstratives used during the trial held September 12-14, 2022, by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6)(Gattuso, Dominick) Modified on 12/15/2022 (nms). (Entered: 12/15/2022) (Main Document) (5) |
| Dec 15, 2022 | 230 | NOTICE of Lodging of Defendants' Trial Demonstratives used during the trial held September 12-14, 2022, by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6)(Gattuso, Dominick) Modified on 12/15/2022 (nms). (Entered: 12/15/2022) (Exhibit 1) (30) |
| Dec 15, 2022 | 230 | NOTICE of Lodging of Defendants' Trial Demonstratives used during the trial held September 12-14, 2022, by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6)(Gattuso, Dominick) Modified on 12/15/2022 (nms). (Entered: 12/15/2022) (Exhibit 2) (30) |
| Dec 15, 2022 | 230 | NOTICE of Lodging of Defendants' Trial Demonstratives used during the trial held September 12-14, 2022, by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6)(Gattuso, Dominick) Modified on 12/15/2022 (nms). (Entered: 12/15/2022) (Exhibit 3) (30) |
| Dec 15, 2022 | 230 | NOTICE of Lodging of Defendants' Trial Demonstratives used during the trial held September 12-14, 2022, by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6)(Gattuso, Dominick) Modified on 12/15/2022 (nms). (Entered: 12/15/2022) (Exhibit 4) (30) |
| Dec 15, 2022 | 230 | NOTICE of Lodging of Defendants' Trial Demonstratives used during the trial held September 12-14, 2022, by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6)(Gattuso, Dominick) Modified on 12/15/2022 (nms). (Entered: 12/15/2022) (Exhibit 5) (13) |
| Dec 15, 2022 | 230 | NOTICE of Lodging of Defendants' Trial Demonstratives used during the trial held September 12-14, 2022, by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6)(Gattuso, Dominick) Modified on 12/15/2022 (nms). (Entered: 12/15/2022) (Exhibit 6) (9) |
| Nov 7, 2022 | 228 | POST-Trial Brief Regarding the '659 Patent, by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd.. (Seaman, John) Modified on 11/7/2022 (nms). (Entered: 11/07/2022) (30) |
| Nov 7, 2022 | 229 | Proposed Findings of Fact by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd.. (Seaman, John) (Main Document 229 replaced on 1/17/2023) (nms). (Entered: 11/07/2022) (30) |
| Nov 4, 2022 | 226 | STIPULATION and [Proposed] Order Regarding Post-Trial Briefing for U.S. Patent No. 8,796,331 by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 11/04/2022) (6) |
| Nov 4, 2022 | 227 | SO ORDERED Granting (D.I. 374 in 19-cv-2053-RGA; D.I. 598 in 19-cv-1979-RGA; D.I. 226 in 19-cv-2021-RGA; D.I. 886 in 20-md-2930-RGA) Stipulation and Proposed Order Regarding Post-Trial Briefing for U.S. Patent No. 8,796,331. Signed by Judge Richard G. Andrews on 11/4/2022. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA, 1:19-cv-02021-RGA, 1:19-cv-02053-RGA(nms) (Entered: 11/04/2022) (6) |
| Nov 1, 2022 | 222 | Official Transcript of Pretrial Conference held on 9/1/22 before Judge Richard G. Andrews. Court Reporter Heather M. Triozzi,Email: Heather_Triozzi@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 11/22/2022. Redacted Transcript Deadline set for 12/2/2022. Release of Transcript Restriction set for 1/30/2023. (Triozzi, Heather) (Entered: 11/01/2022) (50) |
| Nov 1, 2022 | 223 | Official Transcript of Bench Trial held on 9/12/22 before Judge Richard G. Andrews. Court Reporter Heather M. Triozzi,Email: Heather_Triozzi@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 11/22/2022. Redacted Transcript Deadline set for 12/2/2022. Release of Transcript Restriction set for 1/30/2023. (Triozzi, Heather) (Entered: 11/01/2022) (267) |
| Nov 1, 2022 | 224 | Official Transcript of Bench Trial held on 9/13/22 before Judge Richard G. Andrews. Court Reporter Heather M. Triozzi,Email: Heather_Triozzi@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 11/22/2022. Redacted Transcript Deadline set for 12/2/2022. Release of Transcript Restriction set for 1/30/2023. (Triozzi, Heather) (Entered: 11/01/2022) (240) |
| Nov 1, 2022 | 225 | Official Transcript of Bench Trial held on 9/14/22 before Judge Richard G. Andrews. Court Reporter Heather M. Triozzi,Email: Heather_Triozzi@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 11/22/2022. Redacted Transcript Deadline set for 12/2/2022. Release of Transcript Restriction set for 1/30/2023. (Triozzi, Heather) (Entered: 11/01/2022) (63) |
| Sep 26, 2022 | 221 | SO ORDERED Granting (D.I. 564 in 19-cv-1979-RGA; D.I. 220 in 19-cv-2021-RGA; D.I. 367 in 19-cv-2053-RGA; D.I. 839 in 20-md-2930-RGA) Stipulation and Order Regarding Post-Trial Briefing. Signed by Judge Richard G. Andrews on 9/26/2022. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA, 1:19-cv-02021-RGA, 1:19-cv-02053-RGA(nms) (Entered: 09/26/2022) (6) |
| Sep 23, 2022 | 220 | STIPULATION and Order Regarding Post Trial Briefing by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Gattuso, Dominick) (Entered: 09/23/2022) (6) |
| Sep 21, 2022 | 216 | Letter to The Honorable Richard G. Andrews from Daniel M. Silver, Esq. regarding courtesy copies of the exhibits. (Silver, Daniel) (Entered: 09/21/2022) (1) |
| Sep 21, 2022 | 217 | REDACTED VERSION of 194 Proposed Pretrial Order, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits 1-12B)(Silver, Daniel) Modified on 9/21/2022 (nms). (Entered: 09/21/2022) (Main Document) (30) |
| Sep 21, 2022 | 218 | REDACTED VERSION of 204 Proposed Pretrial Order, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 9/21/2022 (nms). (Entered: 09/21/2022) (30) |
| Sep 21, 2022 | 219 | STIPULATION TO EXTEND TIME for the parties to submit a post-trial briefing schedule, from September 21, 2022 to September 23, 2022 - filed by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc.,, Torrent Pharmaceuticals Ltd., Hetero USA Inc.. (Ormerod, Eve) (Entered: 09/21/2022) (5) |
| Sep 21, 2022 | 217 | REDACTED VERSION of 194 Proposed Pretrial Order, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits 1-12B)(Silver, Daniel) Modified on 9/21/2022 (nms). (Entered: 09/21/2022) (Exhibit 1-12B) (30) |
| Sep 20, 2022 | 215 | Admitted Trial Exhibits for Bench Trial held 9/12/2022, through 9/14/2022, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 9/20/2022 (nms). (Entered: 09/20/2022) (15) |
| Sep 16, 2022 | 214 | STIPULATION and Proposed Order to Extend Time to file redacted versions of (1) Proposed Joint Pretrial Order, (2) Revised Proposed Joint Pretrial Order, (3) Suggestion of Remand Proposed Order to September 21, 2022 - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 9/16/2022 (nms). (Entered: 09/16/2022) (6) |
| Sep 15, 2022 | 213 | MULTI MEDIA DOCUMENT in the form of a USB drive containing video depositions for trial witnesses Piotr Kapinski, Ph.D. and Dr. Randy Lee Webb. Filing related to (D.I. 353 in 19-cv-2053-RGA; D.I. 546 in 19-cv-1979-RGA; D.I. 812 in 20-md-2930-RGA; D.I. 211 in 19-cv-2021-RGA) Notice of Lodging of Multimedia Filing. (Media on file in Clerk's Office). Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA, 1:19-cv-02021-RGA, 1:19-cv-02053-RGA(nms) (Entered: 09/15/2022) (0) |
| Sep 14, 2022 | 211 | NOTICE of Lodging of Multimedia Filing by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Attachments: # 1 Letter)(Gattuso, Dominick) Modified on 9/15/2022 (nms). (Entered: 09/14/2022) (Main Document) (4) |
| Sep 14, 2022 | 212 | Witness List for Bench Trial held 9/12/2022, through 9/14/2022. (nms) (Entered: 09/14/2022) (3) |
| Sep 14, 2022 | 211 | NOTICE of Lodging of Multimedia Filing by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Attachments: # 1 Letter)(Gattuso, Dominick) Modified on 9/15/2022 (nms). (Entered: 09/14/2022) (Cover Letter) (1) |
| Sep 9, 2022 | 209 | MEMORANDUM ORDER Denying Plaintiff's Motion to Preclude Portions of Dr. Fintel's Testimony (see Memorandum Order for further details). Signed by Judge Richard G. Andrews on 9/9/2022. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA, 1:19-cv-02021-RGA, 1:19-cv-02053-RGA, 1:20-cv-00445-RGA(nms) (Entered: 09/09/2022) (3) |
| Sep 9, 2022 | 210 | NOTICE of Appearance by Daniel John McBride on behalf of Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd. (McBride, Daniel) (Entered: 09/09/2022) (1) |
| Sep 7, 2022 | 205 | ORDER AFTER PRETRIAL CONFERENCE (see Order for further details). Signed by Judge Richard G. Andrews on 9/7/2022. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA, 1:19-cv-02021-RGA, 1:19-cv-02053-RGA, 1:20-cv-00445-RGA(nms) (Entered: 09/07/2022) (2) |
| Sep 7, 2022 | 206 | Letter to The Honorable Richard G. Andrews from Daniel M. Silver, Esq. regarding enclosing Curriculum Vitae for experts. (Attachments: # 1 Curriculum Vitae for Francis G. Spinale, # 2 Curriculum Vitae for Alexander M. Klibanov)(Silver, Daniel) (Entered: 09/07/2022) (Main Document) (1) |
| Sep 7, 2022 | 207 | [SEALED] ORDER Granting Joint Pretrial Order (D.I. 243 in 20-cv-445-RGA; D.I. 769 in 20-md-2930-RGA; D.I. 204 in 19-cv-2021-RGA; D.I. 534 in 19-cv-1979-RGA: D.I. 347 in 19-cv-2053-RGA). Signed by Judge Richard G. Andrews on 9/7/2022.*This order has been emailed to local counsel. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA, 1:19-cv-02021-RGA, 1:19-cv-02053-RGA, 1:20-cv-00445-RGA(nms) (Entered: 09/07/2022) (0) |
| Sep 7, 2022 | 208 | Letter to The Honorable Richard G. Andrews from Dominick T. Gattuso, Esquire regarding CV of Experts. (Attachments: # 1 Exhibit, # 2 Exhibit, # 3 Exhibit)(Gattuso, Dominick) (Entered: 09/07/2022) (Main Document) (1) |
| Sep 7, 2022 | 208 | Letter to The Honorable Richard G. Andrews from Dominick T. Gattuso, Esquire regarding CV of Experts. (Attachments: # 1 Exhibit, # 2 Exhibit, # 3 Exhibit)(Gattuso, Dominick) (Entered: 09/07/2022) (Exhibit) (19) |
| Sep 7, 2022 | 208 | Letter to The Honorable Richard G. Andrews from Dominick T. Gattuso, Esquire regarding CV of Experts. (Attachments: # 1 Exhibit, # 2 Exhibit, # 3 Exhibit)(Gattuso, Dominick) (Entered: 09/07/2022) (Exhibit) (21) |
| Sep 7, 2022 | 208 | Letter to The Honorable Richard G. Andrews from Dominick T. Gattuso, Esquire regarding CV of Experts. (Attachments: # 1 Exhibit, # 2 Exhibit, # 3 Exhibit)(Gattuso, Dominick) (Entered: 09/07/2022) (Exhibit) (29) |
| Sep 7, 2022 | 206 | Letter to The Honorable Richard G. Andrews from Daniel M. Silver, Esq. regarding enclosing Curriculum Vitae for experts. (Attachments: # 1 Curriculum Vitae for Francis G. Spinale, # 2 Curriculum Vitae for Alexander M. Klibanov)(Silver, Daniel) (Entered: 09/07/2022) (Curriculum Vitae for Francis G. Spinale) (30) |
| Sep 7, 2022 | 206 | Letter to The Honorable Richard G. Andrews from Daniel M. Silver, Esq. regarding enclosing Curriculum Vitae for experts. (Attachments: # 1 Curriculum Vitae for Francis G. Spinale, # 2 Curriculum Vitae for Alexander M. Klibanov)(Silver, Daniel) (Entered: 09/07/2022) (Curriculum Vitae for Alexander M. Klibanov) (30) |
| Sep 6, 2022 | 200 | Joint Letter to The Honorable Richard G. Andrews from Adam W. Poff regarding Commercial Success Experts. (Poff, Adam) (Entered: 09/06/2022) (2) |
| Sep 6, 2022 | 201 | REDACTED VERSION of 192 MOTION in Limine to Preclude Dr. Steed's Written Description Opinions Concerning the Characterization of LCZ696 the Rely on Irrelevant Material, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 9/6/2022 (nms). (Entered: 09/06/2022) (17) |
| Sep 6, 2022 | 202 | REDACTED VERSION of 193 Appendix, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 9/6/2022 (nms). (Entered: 09/06/2022) (30) |
| Sep 6, 2022 | 203 | REDACTED VERSION of 191 Appendix, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Part 2, # 2 Part 3, # 3 Part 4, # 4 Part 5, # 5 Part 6, # 6 Part 7, # 7 Part 8, # 8 Part 9, # 9 Part 10)(Joyce, Alexandra) Modified on 9/6/2022 (nms). (Entered: 09/06/2022) (Main Document) (30) |
| Sep 6, 2022 | 204 | [SEALED] Proposed Pretrial Order (*dispute Paragraph 174), by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 9/7/2022 (nms). (Entered: 09/06/2022) (0) |
| Sep 6, 2022 | 203 | REDACTED VERSION of 191 Appendix, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Part 2, # 2 Part 3, # 3 Part 4, # 4 Part 5, # 5 Part 6, # 6 Part 7, # 7 Part 8, # 8 Part 9, # 9 Part 10)(Joyce, Alexandra) Modified on 9/6/2022 (nms). (Entered: 09/06/2022) (Pt. 2 of 10) (30) |
| Sep 6, 2022 | 203 | REDACTED VERSION of 191 Appendix, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Part 2, # 2 Part 3, # 3 Part 4, # 4 Part 5, # 5 Part 6, # 6 Part 7, # 7 Part 8, # 8 Part 9, # 9 Part 10)(Joyce, Alexandra) Modified on 9/6/2022 (nms). (Entered: 09/06/2022) (Pt. 3 of 10) (30) |
| Sep 6, 2022 | 203 | REDACTED VERSION of 191 Appendix, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Part 2, # 2 Part 3, # 3 Part 4, # 4 Part 5, # 5 Part 6, # 6 Part 7, # 7 Part 8, # 8 Part 9, # 9 Part 10)(Joyce, Alexandra) Modified on 9/6/2022 (nms). (Entered: 09/06/2022) (Pt. 4 of 10) (30) |
| Sep 6, 2022 | 203 | REDACTED VERSION of 191 Appendix, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Part 2, # 2 Part 3, # 3 Part 4, # 4 Part 5, # 5 Part 6, # 6 Part 7, # 7 Part 8, # 8 Part 9, # 9 Part 10)(Joyce, Alexandra) Modified on 9/6/2022 (nms). (Entered: 09/06/2022) (Pt. 5 of 10) (12) |
| Sep 6, 2022 | 203 | REDACTED VERSION of 191 Appendix, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Part 2, # 2 Part 3, # 3 Part 4, # 4 Part 5, # 5 Part 6, # 6 Part 7, # 7 Part 8, # 8 Part 9, # 9 Part 10)(Joyce, Alexandra) Modified on 9/6/2022 (nms). (Entered: 09/06/2022) (Pt. 6 of 10) (30) |
| Sep 6, 2022 | 203 | REDACTED VERSION of 191 Appendix, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Part 2, # 2 Part 3, # 3 Part 4, # 4 Part 5, # 5 Part 6, # 6 Part 7, # 7 Part 8, # 8 Part 9, # 9 Part 10)(Joyce, Alexandra) Modified on 9/6/2022 (nms). (Entered: 09/06/2022) (Pt. 7 of 10) (30) |
| Sep 6, 2022 | 203 | REDACTED VERSION of 191 Appendix, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Part 2, # 2 Part 3, # 3 Part 4, # 4 Part 5, # 5 Part 6, # 6 Part 7, # 7 Part 8, # 8 Part 9, # 9 Part 10)(Joyce, Alexandra) Modified on 9/6/2022 (nms). (Entered: 09/06/2022) (Pt. 8 of 10) (26) |
| Sep 6, 2022 | 203 | REDACTED VERSION of 191 Appendix, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Part 2, # 2 Part 3, # 3 Part 4, # 4 Part 5, # 5 Part 6, # 6 Part 7, # 7 Part 8, # 8 Part 9, # 9 Part 10)(Joyce, Alexandra) Modified on 9/6/2022 (nms). (Entered: 09/06/2022) (Pt. 9 of 10) (29) |
| Sep 6, 2022 | 203 | REDACTED VERSION of 191 Appendix, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Part 2, # 2 Part 3, # 3 Part 4, # 4 Part 5, # 5 Part 6, # 6 Part 7, # 7 Part 8, # 8 Part 9, # 9 Part 10)(Joyce, Alexandra) Modified on 9/6/2022 (nms). (Entered: 09/06/2022) (Pt. 10 of 10) (30) |
| Aug 29, 2022 | 198 | REDACTED VERSION of 186 Stipulation, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 8/29/2022 (nms). (Entered: 08/29/2022) (3) |
| Aug 29, 2022 | 199 | REDACTED VERSION of 188 Order, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 8/29/2022 (nms). (Entered: 08/29/2022) (3) |
| Aug 26, 2022 | 196 | ORDER SETTING TRIAL DATES: Trial on the validity of U.S. Patent Nos. 8,101,659 (the 659 patent) and 8,796,331 (the 331 patent) is scheduled for September 12 to September 14, 2022, beginning each day at 8:30 a.m., and ending each day by 5:00 p.m. Trial on the validity of U.S. Patent Nos. 8,877,938 (the 938 patent) and 9,388,134 (the 134 patent) is scheduled for October 18, 2022, beginning at 8:30 a.m. and ending by 5:00 p.m. (see Order for further details). Signed by Judge Richard G. Andrews on 8/26/2022. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA, 1:19-cv-02021-RGA, 1:19-cv-02053-RGA(nms) (Entered: 08/26/2022) (4) |
| Aug 26, 2022 | 197 | REDACTED VERSION of 185 Letter, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 8/26/2022 (nms). (Entered: 08/26/2022) (10) |
| Aug 25, 2022 | 195 | Letter to The Honorable Richard G. Andrews from Daniel M. Silver, Esq. regarding Proposed Order Setting the Schedule for the Trial Dates. (Attachments: # 1 Text of Proposed Order Setting Trial Dates)(Joyce, Alexandra) (Entered: 08/25/2022) (Main Document) (4) |
| Aug 25, 2022 | 195 | Letter to The Honorable Richard G. Andrews from Daniel M. Silver, Esq. regarding Proposed Order Setting the Schedule for the Trial Dates. (Attachments: # 1 Text of Proposed Order Setting Trial Dates)(Joyce, Alexandra) (Entered: 08/25/2022) (Text of Proposed Order Setting Trial Dates) (4) |
| Aug 24, 2022 | 190 | MOTION in Limine to Preclude Defendants' Reliance on Non-Prior Art Documents as Evidence of the State of the Art and a POSA's Understanding - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 8/24/2022 (nms). (Entered: 08/24/2022) (16) |
| Aug 24, 2022 | 191 | [SEALED] APPENDIX re 190 MOTION in Limine to Preclude Defendants' Reliance on Non-Prior Art Documents as Evidence of the State of the Art and a POSA's Understanding, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits 1-19 part 1, # 2 Exhibits 1-19 part 2, # 3 Exhibits 1-19 part 3, # 4 Exhibits 1-19 part 4, # 5 Exhibits 1-19 part 5, # 6 Exhibits 1- 19 part 6, # 7 Exhibits 1-19 part 7, # 8 Exhibits 1-19 part 8, # 9 Exhibits 1-19 part 9, # 10 Exhibits 1-19 part 10, # 11 Exhibits 1-19 part 11, # 12 Certificate of Service)(Silver, Daniel) Modified on 8/24/2022 (nms). (Entered: 08/24/2022) (0) |
| Aug 24, 2022 | 192 | [SEALED] MOTION in Limine to Preclude Dr. Steed's Written Description Opinions Concerning the Characterization of LCZ696 the Rely on Irrelevant Material - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certificate of Service)(Silver, Daniel) Modified on 8/24/2022 (nms). (Entered: 08/24/2022) (0) |
| Aug 24, 2022 | 193 | [SEALED] APPENDIX re 192 MOTION in Limine to Preclude Dr. Steed's Written Description Opinions Concerning the Characterization of LCZ696 the Rely on Irrelevant Material, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits 1-11 part 1, # 2 Exhibits 1-11 part 2, # 3 Certificate of Service)(Silver, Daniel) Modified on 8/24/2022 (nms). (Entered: 08/24/2022) (0) |
| Aug 24, 2022 | 194 | [SEALED] Proposed Pretrial Order by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 1, # 2 Exhibit 1B, # 3 Exhibit 1F, # 4 Exhibit 1I, # 5 Exhibit 2, # 6 Exhibit 3, # 7 Exhibit 3B, # 8 Exhibit 3F, # 9 Exhibit 3I, # 10 Exhibit 4, # 11 Exhibit 5, # 12 Exhibit 5A, # 13 Exhibit 6, # 14 Exhibit 6B, # 15 Exhibit 7, # 16 Exhibit 7B, # 17 Exhibit 8, # 18 Exhibit 8B, # 19 Exhibit 9, # 20 Exhibit 10, # 21 Exhibit 10B, # 22 Exhibit 11, # 23 Exhibit 12, # 24 Exhibit 12B)(Silver, Daniel) (Entered: 08/24/2022) (0) |
| Aug 18, 2022 | 189 | ORAL ORDER: The Pretrial Conference in advance of the invalidity trial is now rescheduled for 9/1/2022, at 3:30 PM in Courtroom 6A. Ordered by Judge Richard G. Andrews on 8/18/2022. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA, 1:19-cv-02021-RGA, 1:19-cv-02053-RGA, 1:20-cv-00445-RGA(nms) (Entered: 08/18/2022) (0) |
| Aug 17, 2022 | 186 | [SEALED] STIPULATION and [Proposed] Order Regarding Defendant Macleod's Infringement of U.S. Patent No. 8,101,659 by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 08/17/2022) (0) |
| Aug 17, 2022 | 187 | ORAL ORDER: Due to a scheduling conflict the Pretrial Conference set for 8/26/2022, is CANCELED. The conference will be rescheduled for a date to be determined. Ordered by Judge Richard G. Andrews on 8/17/2022. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA, 1:19-cv-02021-RGA, 1:19-cv-02053-RGA, 1:20-cv-00445-RGA(nms) (Entered: 08/17/2022) (0) |
| Aug 17, 2022 | 188 | [SEALED] ORDER Granting (D.I. 723 in 20-md-2930-RGA; D.I. 186 in 19-cv-2021-RGA) STIPULATION and [Proposed] Order Regarding Defendant Macleod's Infringement of U.S. Patent No. 8,101,659. Signed by Judge Richard G. Andrews on 8/17/2022.*This order has been emailed to local counsel. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-02021-RGA(nms) (Entered: 08/17/2022) (0) |
| Aug 16, 2022 | 185 | [SEALED] Joint Letter to The Honorable Richard G. Andrews from Daniel M. Silver, Esq. regarding Scheduling of the Three-Day Validity Trial for United States Patent Nos. 8,101,659 (the '659 patent), 8,796,331 (the '331 patent), 8,877,938 (the '938 patent), and 9,388,134 (the '134 patent). (Attachments: # 1 Certificate of Service)(Silver, Daniel) (Entered: 08/16/2022) (0) |
| Aug 12, 2022 | 184 | NOTICE of Pursuant to 35 U.S.C. § 282, by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd.. (Ferraro, April) Modified on 8/13/2022 (nms). (Entered: 08/12/2022) (15) |
| Aug 3, 2022 | 183 | Letter (2) Docket Text: Letter to The Honorable Richard G. Andrews from Adam W. Poff regarding '659 and '331 patent infringement trial. (Poff, Adam) |
| Jul 22, 2022 | 180 | Reply Brief (16) Docket Text: REPLY BRIEF re [175] MOTION to Preclude Defendants' Expert Dr. Fintel from Offering Opinions on Topics Outside His Expertise, filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 7/24/2022 (nms). |
| Jul 22, 2022 | 181 | Main Document (4) Docket Text: DECLARATION of Shannon K. Clark, Esq. re [180] in Reply Brief, by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibits I-M)(Silver, Daniel) Modified on 7/25/2022 (nms). |
| Jul 22, 2022 | 181 | Exhibit I-M (75) |
| Jul 22, 2022 | 182 | Redacted Document (30) Docket Text: REDACTED VERSION of [179] Answering Brief in Opposition, by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd.. (Hoeschen, Nathan) |
| Jul 14, 2022 | 178 | Status Report (9) Docket Text: Joint Status Report, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 7/15/2022 (nms). |
| Jul 12, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (D.I. 479 in 19-cv-1979-RGA; D.I. 208 in 20-cv-445-RGA; D.I. 674 in 20-md-2930-RGA; D.I. 177 in 19-cv-2021-RGA; D.I. 306 in 19-cv-2053-RGA) Stipulation and Proposed Order to Extend Time Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA, 1:19-cv-02021-RGA, 1:19-cv-02053-RGA, 1:20-cv-00445-RGA(nms) |
| Jul 7, 2022 | 177 | Stipulation (7) Docket Text: STIPULATION and Proposed Order to Extend Time, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 7/7/2022 (nms). |
| Jul 1, 2022 | 175 | Main Document (9) Docket Text: MOTION to Preclude Expert Dr. Fintel from Offering Opinions on Topics Outside His Expertise - filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) 7.1.1. Certification, # (2) Proposed Order)(Silver, Daniel) Modified on 7/5/2022 (nms). |
| Jul 1, 2022 | 175 | Rule 7.1.1. Certification (1) |
| Jul 1, 2022 | 175 | Text of Proposed Order (4) |
| Jul 1, 2022 | 176 | Main Document (4) Docket Text: DECLARATION of Shannon K. Clark, Esq. re [175] MOTION to Preclude Expert Dr. Fintel from Offering Opinions on Topics Outside His Expertise, by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibits A-H)(Silver, Daniel) Modified on 7/5/2022 (nms). |
| Jul 1, 2022 | 176 | Exhibit A-H (222) |
| Jun 17, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (D.I. 646 in 20-md-2930-RGA; D.I. 196 in 20-cv-445-RGA; D.I. 468 in 19-cv-1979-RGA; D.I. 293 in 19-cv-2053-RGA; D.I. 174 in 19-cv-2021-RGA) STIPULATION and Proposed Order to Extend Time to submit a joint interim status report to July 7, 2022. Signed by Judge Richard G. Andrews on 6/17/2022. Associated Cases: 1:19-cv-01979-RGA, 1:19-cv-02021-RGA, 1:19-cv-02053-RGA, 1:20-cv-00445-RGA, 1:20-md-02930-RGA(nms) |
| Jun 17, 2022 | 174 | Stipulation to EXTEND Time (7) Docket Text: STIPULATION and Proposed Order to Extend Time for the parties to submit a joint interim status report to July 7, 2022 - filed by Mylan Pharmaceuticals Inc.. (Palapura, Bindu) Modified on 6/17/2022 (nms). |
| Jun 16, 2022 | 173 | Notice to Take Deposition (11) Docket Text: NOTICE to Take Deposition of Dr. Gregory Bell, Ph.D. on June 17, 2022 filed by Laurus Generics Inc., Laurus Labs Limited.(Poff, Adam) |
| Jun 15, 2022 | 172 | Notice to Take Deposition (8) Docket Text: NOTICE to Take Deposition of Alexander M. Klibanov, Ph.D. on June 16, 2022 (remote) filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) |
| Jun 14, 2022 | 171 | Letter (3) Docket Text: Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., regarding the Courts June 3, 2022 Oral Order concerning patent expiration dates. (Silver, Daniel) Modified on 6/14/2022 (nms). |
| Jun 13, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (D.I. 282 in 19-cv-2053-RGA; D.I. 170 in 19-cv-2021-RGA; D.I. 459 in19-cv-1979-RGA; D.I. 628 in 20-md-2930-RGA; D.I. 188 in 20-cv-445-RGA)STIPULATION to Extend Time for the close of expert discovery to complete the depositions. Signed by Judge Richard G. Andrews on 6/13/2022. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA, 1:19-cv-02021-RGA, 1:19-cv-02053-RGA, 1:20-cv-00445-RGA(nms) |
| Jun 10, 2022 | 170 | Stipulation to EXTEND Time (7) Docket Text: STIPULATION and Proposed Order Extending Time for the close of expert discovery to complete the depositions - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 6/13/2022 (nms). |
| Jun 6, 2022 | 168 | Notice (Other) (5) Docket Text: NOTICE of Defendants' Deposition of Adam J. Matzger, Ph.D. by Crystal Pharmaceutical (Suzhou) Co., Ltd. (Gattuso, Dominick) |
| Jun 6, 2022 | 169 | Notice to Take Deposition (4) Docket Text: NOTICE to Take Deposition of Dr. Jonathan W. Steed filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| Jun 3, 2022 | N/A | Oral Order (0) Docket Text: ORAL ORDER: It appears that the 30 month stay ends no earlier than July 7, 2023. (E.g., No. 19-1979, D.I. 3). Two of the asserted patents (the 659 and the 331) are said to expire on January 14, 2023. (Id.). The other two patents (the 938 and the 134) expire in 2026 and 2027. I think Novartis told me on April 21, 2022, that the first two patents, because of pediatric (or some other) exclusivity, if valid and infringed, would actually block any launch before July 14, 2023. The parties are to advise whether I have all this right. If it is right, I expect to prioritize the invalidity and infringement proceedings relating to the second set of patents. I do not see what sense it makes to invest a lot of time and effort trying cases relating to patents that may have no practical impact and at most would have limited practical impact. If one or more generics (which, by my count, are Biocon, Laurus, Teva, MacLeods, Zydus, Hetero, and DRL (Mylans trials being in West Virginia)) are successful against the later-expiring patents, there will be other ways to resolve the 659 and 331 claims. Ordered by Judge Richard G. Andrews on 6/3/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| May 26, 2022 | 166 | Notice to Take Deposition (4) Docket Text: NOTICE to Take Deposition of Dan Fintel, M.D. filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| May 25, 2022 | 165 | Notice to Take Deposition (4) Docket Text: NOTICE to Take Deposition of Dr. Laird Forrest filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| May 17, 2022 | 164 | Notice to Take Deposition (4) Docket Text: NOTICE to Take Deposition of Ivan T. Hofmann filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| May 16, 2022 | N/A | CORRECTING ENTRY: (0) Docket Text: CORRECTING ENTRY: The Notice of Service (D.I. 577 in 20md2930-RGA; D.I. 437 in 19cv199-RGA; D.I. 164 19cv2021-RGA; D.I. 258 in 19cv2053-RGA; D.I. 178 in 20cv445-RGA) filed on 5/13/2022, has been removed. The filing contained errors in the caption. Counsel shall refile the Notice of Service and reflect "RGA" after the case numbers. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA, 1:19-cv-02021-RGA, 1:19-cv-02053-RGA, 1:20-cv-00445-RGA(nms) |
| May 3, 2022 | 163 | Notice of Service (11) Docket Text: NOTICE OF SERVICE of Supplemental Sur-Reply Expert Report of Dr. Alexander M. Klibanov on the Validity of the '659 Patent filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Apr 28, 2022 | 162 | Letter (2) Docket Text: Letter to The Honorable Richard G. Andrews from Adam W. Poff regarding Defendants' request for trial date on infringement of the '659 and '331 patents. (Poff, Adam) |
| Apr 21, 2022 | N/A | Status Conference (0) Docket Text: Minute Entry for proceedings held before Judge Richard G. Andrews - Status/scheduling Conference held on 4/21/2022. Counsel for Plaintiff: D. Silver. Counsel for Defendants: D. Gattuso, K. Keller, J. Miller, D. Bortz, M. Haney, C. Hitch, A. Poff, J. Seaman, S. Stamoulis. The parties shall submit proposed scheduled two weeks from today. (Court Reporter Heather Triozzi.) Associated Cases: 1:20-md-02930-RGA et al.(lak) |
| Apr 20, 2022 | 160 | Notice of Service (12) Docket Text: NOTICE OF SERVICE of (1) Sur-Reply Expert Report of Francis G. Spinale, MD, PH.D. regarding Validity and (2) Sur-Reply Report of Gregory K. Bell, Ph.D. filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| Apr 20, 2022 | 161 | Notice of Service (11) Docket Text: NOTICE OF SERVICE of Sur-Reply Expert Report of Dr. Alexander M. Klibanov on the Validity of the 659 and 331 Patents filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| Apr 11, 2022 | N/A | Case No Longer Referred to Mediation (0) Docket Text: CASE NO LONGER REFERRED to Magistrate Judge Burke for the purpose of exploring ADR. Please see the Court's Standing Order No. 2022-2 dated March 14, 2022. (dlb) |
| Apr 11, 2022 | N/A | Oral Order (0) Docket Text: ORAL ORDER: Due to a scheduling conflict the Status/Scheduling Conference scheduled for 4/20/2022, is CANCELED. The Status/Scheduling Conference is now rescheduled for 4/21/2022, at 2:00 PM in Courtroom 6A. Ordered by Judge Richard G. Andrews on 4/11/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| Apr 4, 2022 | N/A | Oral Order (0) Docket Text: ORAL ORDER: A Status/Scheduling Conference is now set for 4/20/2022, at 2:00 PM in Courtroom 6A. Ordered by Judge Richard G. Andrews on 4/4/2022. Associated Cases: 1:19-cv-01979-RGA, 1:19-cv-02021-RGA, 1:19-cv-02053-RGA, 1:20-cv-00074-RGA, 1:20-cv-00415-RGA(nms) |
| Apr 1, 2022 | 156 | Notice of Service (4) Docket Text: NOTICE OF SERVICE of Reply Expert Report of Dr. Jonathan W. Steed filed by Teva Pharmaceuticals USA, Inc..(Hoeschen, Nathan) |
| Apr 1, 2022 | 157 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of the Reply Expert Report of Dan Fintel, M.D., on the Invalidity of the '659 and '331 Patents filed by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc.,, Torrent Pharmaceuticals Ltd., Hetero USA Inc..(Ormerod, Eve) |
| Mar 29, 2022 | 155 | Redacted Document (6) Docket Text: REDACTED VERSION of [153] Stipulation, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 3/29/2022 (nms). |
| Mar 21, 2022 | 152 | Status Report (17) Docket Text: JOINT Status Report, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 3/22/2022 (nms). |
| Mar 16, 2022 | N/A | Oral Order (0) Docket Text: ORAL ORDER: The parties to the MDL and its member cases are to file a joint status report no later than three (3) days from the date of this Order. Specifically the parties should address (1) scheduled deadlines and events currently in place, (2) matters that are outstanding and need Court attention, and (3) for the cases related to the MDL but not member cases of the MDL, what the relationship is, including in particular what overlap (for example, the same patents, different patents but the same patent family, the same branded products, the same generic products) the related cases have with the member cases. Ordered by Judge Richard G. Andrews on 3/16/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| Mar 15, 2022 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Reassigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA, 1:19-cv-02021-RGA, 1:19-cv-02053-RGA, 1:20-cv-00074-RGA and 1:20-cv-00445-RGA (rjb) |
| Mar 15, 2022 | 150 | Order (1) Docket Text: ORDER in MDL No. 2930 Reassigning Litigation to Judge Richard G. Andrews. Signed by Karen K. Caldwell, Chair on 3/15/22. Associated Cases: 1:20-md-02930-LPS et al. (ntl) |
| Feb 11, 2022 | 148 | Notice of Service (17) Docket Text: NOTICE OF SERVICE of (1) Responsive Expert Report of Francis G. Spinale, MD, PHD Regarding Validity of the 659 and 331 Patents; (2) Responsive Expert Report of Dr. Alexander M. Klibanov on the Validity of the 659 and 331 Patents; and (3) Expert Report of Gregory K. Bell, PH.D. filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| Feb 11, 2022 | 149 | Notice of Service (9) Docket Text: NOTICE OF SERVICE of Responsive Expert Report of Bernhardt L. Trout, Ph.D. filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| Jan 7, 2022 | 147 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of (1) Supplemental Opening Expert Report of Dr. Alexander M. Klibanov on Infringement by Defendants Alembic Pharmaceuticals Limited and Alembic Pharmaceuticals, Inc. and (2) Supplemental Opening Expert Report of Francis G. Spinale, MD, PHD, on Infringement by Defendants Alembic Pharmaceuticals Limited and Alembic Pharmaceuticals, Inc. filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| Jan 6, 2022 | 146 | Notice (Other) (2) Docket Text: NOTICE of Withdrawal of Appearance of Amit Singhai by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc. (Ormerod, Eve) |
| Dec 15, 2021 | 143 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Opening Expert Report of Dan Fintel, M.D., on the Invalidity of the '659 and '331 Patents filed by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc..(Ormerod, Eve) |
| Dec 15, 2021 | 144 | Notice of Service (18) Docket Text: NOTICE OF SERVICE of Opening Expert Reports filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| Dec 15, 2021 | 145 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Opening Expert Report of Laird Forrest Regarding Invalidity of U.S. Patent Nos. 8,101,659 and 8,796,331 filed by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Dr. Reddys Laboratories, Inc..(Stamoulis, Stamatios) |
| Dec 14, 2021 | 142 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Expert Report of Dr. Jonathan W. Steed filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc..(Weinblatt, Richard) |
| Dec 9, 2021 | 141 | Redacted Document (4) Docket Text: REDACTED VERSION of (140 in 1:19-cv-02021-LPS, 110 in 1:20-cv-00074-LPS, 447 in 1:20-md-02930-LPS) Stipulation, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Dec 7, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (140 in 1:19-cv-02021-LPS, 110 in 1:20-cv-00074-LPS, 447 in 1:20-md-02930-LPS) STIPULATION and [Proposed] Order Dismissing Novartis's '938 and '134 Patent Claims Against Alembic and Alembic's Counterclaims Against the '938 and '134 Patents filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 12/6/21. Associated Cases: 1:19-cv-02021-LPS, 1:20-cv-00074-LPS, 1:20-md-02930-LPS (ntl) |
| Nov 29, 2021 | 138 | Redacted Document (3) Docket Text: REDACTED VERSION of (420 in 1:20-md-02930-LPS, 135 in 1:19-cv-02021-LPS, 108 in 1:20-cv-00074-LPS) Stipulation by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| Nov 29, 2021 | 139 | Redacted Document (3) Docket Text: REDACTED VERSION of (423 in 1:20-md-02930-LPS, 136 in 1:19-cv-02021-LPS) Stipulation by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| Nov 24, 2021 | 137 | Redacted Document (4) Docket Text: REDACTED VERSION of (133 in 1:19-cv-02021-LPS, 411 in 1:20-md-02930-LPS) Stipulation of Dismissal by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Nov 19, 2021 | N/A | CORRECTING ENTRY: (0) Docket Text: CORRECTING ENTRY: D.I. 136 deleted per counsels request. (apk) |
| Nov 17, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (133 in 1:19-cv-02021-LPS, 411 in 1:20-md-02930-LPS) STIPULATION of Dismissal of Novartis's '938 and '134 Patent Claims Against Macleods and Macleods's Conterclaims Against the '938 Patent. Signed by Judge Leonard P. Stark on 11/17/21. Associated Cases: 1:19-cv-02021-LPS, 1:20-md-02930-LPS (ntl) |
| Nov 16, 2021 | 134 | Redacted Document (17) Docket Text: REDACTED VERSION of (196 in 1:19-cv-02053-LPS, 114 in 1:20-cv-00415-LPS, 339 in 1:19-cv-01979-LPS, 132 in 1:19-cv-02021-LPS, 35 in 1:21-cv-00229-LPS, 106 in 1:20-cv-00074-LPS, 157 in 1:20-cv-00445-LPS, 407 in 1:20-md-02930-LPS) Status Report by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| Nov 9, 2021 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Whitney M. Howard for Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:20-md-02930-LPS et al.(srs) |
| Nov 8, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (156 in 1:20-cv-00445-LPS, 131 in 1:19-cv-02021-LPS, 105 in 1:20-cv-00074-LPS, 195 in 1:19-cv-02053-LPS, 337 in 1:19-cv-01979-LPS, 405 in 1:20-md-02930-LPS, 113 in 1:20-cv-00415-LPS) MOTION for Pro Hac Vice Appearance of Attorney Whitney Meier Howard filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 11/8/21. Associated Cases: 1:20-md-02930-LPS et al. (ntl) |
| Nov 5, 2021 | 131 | Main Document (3) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Whitney Meier Howard - filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Certification for Whitney Meier Howard)(Silver, Daniel) |
| Nov 5, 2021 | 131 | Certification for Whitney Meier Howard (1) |
| Nov 4, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (336 in 1:19-cv-01979-LPS, 104 in 1:20-cv-00074-LPS, 404 in 1:20-md-02930-LPS, 194 in 1:19-cv-02053-LPS, 130 in 1:19-cv-02021-LPS, 155 in 1:20-cv-00445-LPS, 112 in 1:20-cv-00415-LPS, 34 in 1:21-cv-00229-LPS) STIPULATION TO EXTEND TIME the Deadline for the Submissionof the Joint Status Report to November 8, 2021 filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 11/4/21. Associated Cases: 1:19-cv-01979-LPS et al. (ntl) |
| Nov 3, 2021 | 130 | Stipulation to EXTEND Time (12) Docket Text: STIPULATION TO EXTEND TIME the Deadline for the Submissionof the Joint Status Report to November 8, 2021 - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Oct 21, 2021 | 129 | Notice of Service (18) Docket Text: NOTICE OF SERVICE of (1) Novartis's Objections and Responses to Defendants' First Set of Requests for Admission (Nos. 1-18); (2) Novartis's Objections and Responses to Defendant Teva's First Set of Requests for Admissions (Nos. 1-9); (3) Novartis's Objections and Responses to Defendant Teva's First Set of Individual Interrogatories (Nos. 1-9); and (4) Novartis's Objections and Responses to Defendant Zydus's First Set of Requests for Admissions (Nos. 1-8) filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| Oct 20, 2021 | 124 | Notice of Service (14) Docket Text: NOTICE OF SERVICE of Novartis's Second Supplemental Response to Defendants' Interrogatory No. 3 filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| Oct 20, 2021 | 125 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of 1) Alembic Defendants' Response to Plaintiff's First Set of Requests for Admissions (Nos. 1-50), 2) Alembic Pharmaceuticals Limited's and Alembic Pharmaceuticals, Inc.'s Response to Novartis's Third Set of Interrogatories (No. 6), and 3) Alembic Pharmaceuticals Limited's and Alembic Pharmaceuticals, Inc.'s Response to Novartis's Fourth Set of Requests for the Production of Documents and Things (No. 75) filed by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc..(Ormerod, Eve) |
| Oct 20, 2021 | 126 | Notice to Take Deposition (11) Docket Text: NOTICE to Take Deposition of Michael Motto on October 22, 2021 filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) |
| Oct 20, 2021 | 127 | Notice of Appearance (1) Docket Text: NOTICE of Appearance by April M. Kirby on behalf of Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd. (Kirby, April) |
| Oct 20, 2021 | 128 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of (i) Macleods Pharmaceuticals Ltd. and Macleods Pharma USA, Inc.'s Objections and Responses to Novartis's First Set of Requests for Admission (Nos. 1-27); (ii) Macleods Pharmaceuticals Ltd. and Macleods Pharma USA, Inc.'s Objections and Responses to Novartis's Third Set of Interrogatories (No. 6); (iii) Macleods Pharmaceuticals Ltd. and Macleods Pharma USA, Inc.'s Objections and Responses to Novartis's Fourth Set of Requests for the Production of Documents and Things (No. 75); and (iv) Macleods Pharmaceuticals Ltd. and Macleods Pharma USA, Inc.'s Supplemental Objections and Responses to Novartis's Second Set of Interrogatories (Nos. 3-5) filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Seaman, John) |
| Oct 19, 2021 | 123 | Notice of Service (19) Docket Text: NOTICE OF SERVICE of Discovery Responses filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| Oct 18, 2021 | 122 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Alembic Pharmaceuticals Limited's and Alembic Pharmaceuticals, Inc.'s Responses and Objections to Novartis's Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) filed by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc..(Ormerod, Eve) |
| Oct 1, 2021 | 121 | Notice to Take Deposition (8) Docket Text: NOTICE to Take Deposition of Michael Exton on October 5, 2021 filed by Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd..(Stamoulis, Stamatios) |
| Sep 21, 2021 | 120 | Notice of Service (21) Docket Text: NOTICE OF SERVICE of (1) Novartis's Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) to Defendants, (2) Novartis's Third Set Of Interrogatories To Defendants, (3) Novartis's Fourth Set of Requests to Defendants for the Production of Documents and Things, (4) Novartis's First Set Of Requests For Admissions To Defendants, and (5) Novartis's Second Set of Common Interrogatories to Defendants filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| Sep 20, 2021 | 119 | Notice of Service (19) Docket Text: NOTICE OF SERVICE of (1) Novartis's Objections and Responses to Defendants' Notice of Deposition to Plaintiff Pursuant to Fed. R. Civ. P. 30(b)(6) and (2) Plaintiff's Second Supplemental Infringement Contentions Against Defendants filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| Sep 17, 2021 | 118 | Notice of Service (5) Docket Text: NOTICE OF SERVICE of Defendants' Supplemental Joint Invalidity Contentions filed by Alkem Laboratories Ltd., Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc., Biocon Limited, Biocon Pharma Limited, Biocon Pharma, Inc..(Dorsney, Kenneth) |
| Sep 15, 2021 | 109 | Notice to Take Deposition (11) Docket Text: NOTICE to Take Deposition of Yugang Liu on on a mutually agreed-upon date filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) |
| Sep 15, 2021 | 110 | Notice to Take Deposition (11) Docket Text: NOTICE to Take Deposition of Sven Erik Godtfredsen on a mutually agreed upon date and time filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) |
| Sep 15, 2021 | 111 | Notice to Take Deposition (11) Docket Text: NOTICE to Take Deposition of Paul Sutton on a mutually agreed upon date and time filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) |
| Sep 15, 2021 | 112 | Notice to Take Deposition (11) Docket Text: NOTICE to Take Deposition of Bin Hu on a mutually agreed upon date and time filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) |
| Sep 15, 2021 | 113 | Notice to Take Deposition (11) Docket Text: NOTICE to Take Deposition of Lili Feng on a mutually agreed upon date and time filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) |
| Sep 15, 2021 | 114 | Notice to Take Deposition (11) Docket Text: NOTICE to Take Deposition of Mahavir Prashad on a mutually agreed upon date and time filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) |
| Sep 15, 2021 | 115 | Notice to Take Deposition (11) Docket Text: NOTICE to Take Deposition of Michael J. Girgis on a mutually agreed upon date and time filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) |
| Sep 15, 2021 | 116 | Notice to Take Deposition (11) Docket Text: NOTICE to Take Deposition of Piotr Karpinski on a mutually agreed upon date and time filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) |
| Sep 15, 2021 | 117 | Notice to Take Deposition (11) Docket Text: NOTICE to Take Deposition of Thomas J. Blacklock on a mutually agreed upon date and time filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) |
| Sep 14, 2021 | 108 | Notice of Service (5) Docket Text: NOTICE OF SERVICE of Defendant Crystal Pharma's Second Set of Individual Interrogatories (No. 4) to Plaintiff Novartis Pharmaceuticals Corporation filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) |
| Sep 9, 2021 | N/A | CORRECTING ENTRY: (0) Docket Text: CORRECTING ENTRY: DI 107 previously deleted per counsels request. (apk) |
| Sep 9, 2021 | 107 | Notice (Other) (2) Docket Text: NOTICE of Joinder by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc. (Ormerod, Eve) |
| Sep 8, 2021 | 105 | Notice to Take Deposition (19) Docket Text: NOTICE to Take Deposition of NOVARTIS PHARMACEUTICALS CORPORATION on a mutually agreed upon date and time filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) |
| Sep 8, 2021 | 106 | Notice to Take Deposition (11) Docket Text: NOTICE to Take Deposition of Randy Lee Webb on September 24, 2021 filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) |
| Aug 31, 2021 | 104 | Notice of Service (20) Docket Text: NOTICE OF SERVICE of (1) Plaintiff's First Supplemental Infringement Contentions Against Defendants, and (2) Novartis's First Supplemental Objections and Responses to Defendant's First Set of Individual Interrogatories (Nos. 1-3) filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| Aug 27, 2021 | 103 | Notice of Service (15) Docket Text: NOTICE OF SERVICE of Novartis's Second Supplemental Objections and Responses to Defendants' First Set of Interrogatories (Nos. 1-7) filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Jul 14, 2021 | 101 | Answer to Counterclaim (12) Docket Text: ANSWER to [99] Answer to Amended Complaint, Counterclaim by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Jul 14, 2021 | 102 | Answer to Counterclaim (9) Docket Text: ANSWER to [100] Answer to Amended Complaint,, Counterclaim, by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Jun 23, 2021 | 99 | Answer to Amended Complaint (30) Docket Text: ANSWER to Amended Complaint, re: [97] Amended Complaint, Additional Defenses and, COUNTERCLAIM against Novartis Pharmaceuticals Corporation by Alembic Pharmaceuticals, Inc., Alembic Pharmaceuticals Limited.(Ormerod, Eve) |
| Jun 23, 2021 | 100 | Answer to Amended Complaint (27) Docket Text: ANSWER to Amended Complaint, re: [97] Amended Complaint, Defendants Macleods Pharmaceuticals Ltd. and Macleods Pharma USA, Inc.'s Answer to Amended Complaint and Counterclaims, COUNTERCLAIM against Novartis Pharmaceuticals Corporation by Macleods Pharmaceuticals Ltd., Macleods Pharma USA, Inc..(Seaman, John) |
| Jun 18, 2021 | 98 | Transcript (115) Docket Text: Official Transcript of Claim Construction Hearing held on June 8, 2021 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, email: gaffigan@verizon.net. Transcript may be viewed at the court public terminal or ordered/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 7/9/2021. Redacted Transcript Deadline set for 7/19/2021. Release of Transcript Restriction set for 9/16/2021. (bpg) |
| Jun 9, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (250 in 1:20-md-02930-LPS, 85 in 1:19-cv-02021-LPS, 66 in 1:20-cv-00415-LPS, 236 in 1:19-cv-01979-LPS, 13 in 1:21-cv-00229-LPS, 115 in 1:20-cv-00445-LPS, 63 in 1:20-cv-00074-LPS, 133 in 1:19-cv-02053-LPS) STIPULATION and [Proposed] Order Regarding Plaintiff Novartis Pharmaceuticals Corporation's Amended Complaints. Signed by Judge Leonard P. Stark on 6/9/21. Associated Cases: 1:20-md-02930-LPS et al. (ntl) |
| Jun 9, 2021 | 97 | Main Document (23) Docket Text: AMENDED COMPLAINT against Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc., Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd.- filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit A-D)(Silver, Daniel) |
| Jun 9, 2021 | 97 | Exhibit A-D (67) |
| Jun 8, 2021 | N/A | Markman Hearing (0) Docket Text: Minute Entry for proceedings held before Judge Leonard P. Stark - Markman Hearing (by remote video) held on 6/8/2021. (Court Reporter B. Gaffigan.) Associated Cases: 1:20-md-02930-LPS et al. (ntl) |
| Jun 8, 2021 | N/A | Case Referred to Mediation (0) Docket Text: CASE REFERRED to Magistrate Judge Christopher J. Burke for Mediation. Please see Standing Order dated January 20, 2016, regarding disclosure of confidential ADR communications. A link to the standing order is provided here for your convenience at https://www.ded.uscourts.gov/sites/ded/files/forms/StandingOrderforADR-Mediation.pdf (Taylor, Daniel) |
| Jun 8, 2021 | N/A | Oral Order (0) Docket Text: ORAL ORDER: If during the history of this case, Plaintiff(s) and Defendant(s) jointly wish to schedule a form of alternative dispute resolution ("ADR"), such as mediation, with Judge Burke, they should contact chambers by e-mail at Deborah_Benyo@ded.uscourts.gov or by phone. Additionally, if either side wishes to speak ex parte with Judge Burke regarding ADR matters, they may contact chambers via e-mail or by phone to arrange a time for a call. Ordered by Judge Christopher J. Burke on 6/8/2021. Associated Cases: 1:19-cv-02021-LPS, 1:19-cv-02053-LPS, 1:20-cv-00074-LPS, 1:20-cv-00415-LPS, 1:20-cv-00445-LPS(dlb) |
| Jun 7, 2021 | 95 | Main Document (3) Docket Text: Letter to Chief Judge Leonard P. Stark from Daniel M. Silver, Esq. regarding Dispute Letter - re (261 in 1:20-md-02930-LPS) Order,,. (Attachments: # (1) Exhibit A)(Silver, Daniel) |
| Jun 7, 2021 | 95 | Exhibit A (38) |
| Jun 3, 2021 | N/A | Order (0) Docket Text: ORAL ORDER: IT IS HEREBY ORDERED that the Markman hearing on June 8, 2021 at 10:00 a.m. is available to the public using the following dial-in for audio access: +1 646 828 7666 US -- Meeting ID: 161 238 3790 -- Passcode: 824345 -- One Tap Mobile Public Dial-In Number: +16468287666,,1612383790#,,,,*824345# US. Audio reproduction of the proceeding is strictly prohibited. ORDERED by Judge Leonard P. Stark on 6/3/21. Associated Cases: 1:20-md-02930-LPS et al. (ntl) |
| May 25, 2021 | 93 | Main Document (2) Docket Text: Letter to Chief Judge Leonard P. Stark from Daniel M. Silver, Esq. regarding Claim Construction Hearing. (Attachments: # (1) Exhibit 58)(Silver, Daniel) |
| May 25, 2021 | 93 | Exhibit 58 (13) |
| May 24, 2021 | N/A | Order (0) Docket Text: ORAL ORDER: Having reviewed the parties' letter concerning the claim construction hearing scheduled for June 8 at 10:00 a.m. (C.A. No. 20-md-2930 D.I. 256), IT IS HEREBY ORDERED that each side will be allocated 75 minutes for its presentation. The hearing will be conducted by videoconference technology. Defendants shall submit access information for the Court, including access information for any interested member of the public, in advance of the hearing. The parties may present argument in the order they propose in the letter. IT IS FURTHER ORDERED that each party shall submit any slides or other materials to be referenced at the hearing by no later than June 7 at 4:00 p.m. ORDERED by Judge Leonard P. Stark on 5/24/21. Associated Cases: 1:20-md-02930-LPS et al. (ntl) |
| May 21, 2021 | 88 | Joint Claim Construction Brief (30) Docket Text: JOINT CLAIM CONSTRUCTION BRIEF filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| May 21, 2021 | 89 | Main Document (16) Docket Text: APPENDIX re (14 in 1:21-cv-00229-LPS) Joint Claim Construction Brief, (88 in 1:19-cv-02021-LPS) Joint Claim Construction Brief, (69 in 1:20-cv-00415-LPS) Joint Claim Construction Brief, (118 in 1:20-cv-00445-LPS) Joint Claim Construction Brief, (136 in 1:19-cv-02053-LPS) Joint Claim Construction Brief, (253 in 1:20-md-02930-LPS) Joint Claim Construction Brief, (239 in 1:19-cv-01979-LPS) Joint Claim Construction Brief, (66 in 1:20-cv-00074-LPS) Joint Claim Construction Brief (Volume 1 -- Exhibits A-D) by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit A-D)(Silver, Daniel) |
| May 21, 2021 | 89 | Exhibit A-D (431) |
| May 21, 2021 | 90 | Main Document (16) Docket Text: APPENDIX re (14 in 1:21-cv-00229-LPS) Joint Claim Construction Brief, (88 in 1:19-cv-02021-LPS) Joint Claim Construction Brief, (69 in 1:20-cv-00415-LPS) Joint Claim Construction Brief, (118 in 1:20-cv-00445-LPS) Joint Claim Construction Brief, (136 in 1:19-cv-02053-LPS) Joint Claim Construction Brief, (253 in 1:20-md-02930-LPS) Joint Claim Construction Brief, (239 in 1:19-cv-01979-LPS) Joint Claim Construction Brief, (66 in 1:20-cv-00074-LPS) Joint Claim Construction Brief (Volume 2 -- Exhibits 1-57) by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit 1-29, # (2) Exhibit 35-43, # (3) Exhibit 44, # (4) Exhibit 45-57)(Silver, Daniel) |
| May 21, 2021 | 90 | Exhibit 1-29 (200) |
| May 21, 2021 | 90 | Exhibit 35-43 (83) |
| May 21, 2021 | 90 | Exhibit 44 (54) |
| May 21, 2021 | 90 | Exhibit 45-57 (180) |
| May 21, 2021 | 91 | Letter (2) Docket Text: Letter to The Honorable Chief Judge Leonard P. Stark from Daniel M. Silver, Esq. regarding Claim Construction Hearing. (Silver, Daniel) |
| May 20, 2021 | 87 | Notice of Service (5) Docket Text: NOTICE OF SERVICE of Defendants Objection to Plaintiffs Notice of Deposition of Raymond Butcher, Ph.D., Pursuant to Fed. R. Civ. P. 30(b)(1) filed by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Dr. Reddys Laboratories, Inc..(Stamoulis, Stamatios) |
| May 19, 2021 | 86 | Statement (6) Docket Text: STATEMENT re (241 in 1:20-md-02930-LPS, 228 in 1:19-cv-01979-LPS) Letter Novartis's Comments on Defendants' Technology Tutorial by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| May 18, 2021 | 85 | Main Document (13) Docket Text: STIPULATION and [Proposed] Order Regarding Plaintiff Novartis Pharmaceuticals Corporation's Amended Complaints by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit A-N)(Silver, Daniel) |
| May 18, 2021 | 85 | Exhibit A-N (614) |
| May 17, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (82 in 1:19-cv-02021-LPS, 60 in 1:20-cv-00074-LPS, 112 in 1:20-cv-00445-LPS, 247 in 1:20-md-02930-LPS, 233 in 1:19-cv-01979-LPS, 63 in 1:20-cv-00415-LPS, 12 in 1:21-cv-00229-LPS, 130 in 1:19-cv-02053-LPS) STIPULATION TO EXTEND TIME for Paintiff to Amend or Supplement Pleadings to May 18, 2021 filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 5/17/21. Associated Cases: 1:20-md-02930-LPS et al. (ntl) |
| May 17, 2021 | N/A | Order (0) Docket Text: ORAL ORDER: IT IS HEREBY ORDERED that: (1) the claim construction hearing will be held remotely; (2) the claim construction hearing is RESCHEDULED to June 8, 2021 at 10:00 a.m.; and (3) the parties shall advise the Court, simultaneously with filing their joint claim construction brief, of the number of hours they request for the hearing and whether they prefer to proceed by video or telephone conference. ORDERED by Judge Leonard P. Stark on 5/17/21. Associated Cases: 1:20-md-02930-LPS et al. (ntl) |
| May 17, 2021 | 84 | Notice of Service (4) Docket Text: NOTICE OF SERVICE of Defendants' Joint Sur-Reply Claim Construction Brief [with Exhibit 57]; and, (ii) the Declaration of Raymond Butcher, Ph.D. filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) |
| May 14, 2021 | 82 | Stipulation to EXTEND Time (13) Docket Text: STIPULATION TO EXTEND TIME Deadline for Paintiff to Amend or Supplement Pleadings to May 18, 2021 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| May 11, 2021 | 81 | Notice (Other) (5) Docket Text: NOTICE of Deposition of Raymond Butcher, Ph.D., Pursuant to Fed. R. Civ. P. 30(b)(1) by Novartis Pharmaceuticals Corporation (Silver, Daniel) |
| May 5, 2021 | 80 | Letter (1) Docket Text: Letter to The Honorable Chief Judge Leonard P. Stark from Daniel M. Silver, Esq. regarding Plaintiff's Technology Tutorial. (Silver, Daniel) |
| Apr 29, 2021 | 79 | Notice of Service (16) Docket Text: NOTICE OF SERVICE of (1) Novartis's Reply Claim Construction Brief, (2) Declaration of Laura K. Fishwick, Esq., and (3) Reply Declaration of Alexander M. Klibanov, Ph.D. filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| Apr 21, 2021 | 78 | Notice of Service (15) Docket Text: NOTICE OF SERVICE of Novartis's Objections to Defendants' Notice of Deposition of Alexander M. Klibanov, Ph.D., Pursuant to Fed. R. Civ. P. 30(b)(1) filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Apr 16, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (228 in 1:20-md-02930-LPS, 77 in 1:19-cv-02021-LPS, 55 in 1:20-cv-00074-LPS, 220 in 1:19-cv-01979-LPS) STIPULATION TO EXTEND TIME for Substantial Completion of Document Production to May 14, 2021 filed by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc. Signed by Judge Leonard P. Stark on 4/16/21. Associated Cases: 1:19-cv-01979-LPS, 1:19-cv-02021-LPS, 1:20-cv-00074-LPS, 1:20-md-02930-LPS (ntl) |
| Apr 14, 2021 | 77 | Stipulation to EXTEND Time (3) Docket Text: STIPULATION TO EXTEND TIME for Substantial Completion of Document Production to May 14, 2021 - filed by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc.. (Ormerod, Eve) |
| Mar 31, 2021 | 76 | Notice of Service (4) Docket Text: NOTICE OF SERVICE of (i) Defendants' Joint Responsive Claim Construction Brief [with exhibits]; and, (ii) Declaration of Raymond Butcher, Ph.D. [with exhibits] filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) |
| Mar 30, 2021 | 75 | Notice to Take Deposition (11) Docket Text: NOTICE to Take Deposition of Alexander M. Klibanov, Ph.D., on May 5, 2021 filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) |
| Mar 16, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (223 in 1:20-md-02930-LPS, 52 in 1:20-cv-00074-LPS, 74 in 1:19-cv-02021-LPS, 103 in 1:20-cv-00445-LPS, 215 in 1:19-cv-01979-LPS, 122 in 1:19-cv-02053-LPS, 55 in 1:20-cv-00415-LPS) STIPULATION and [Proposed] Order Extending Deadline to Amend the Pleadings; (51 in 1:20-cv-00074-LPS, 121 in 1:19-cv-02053-LPS, 213 in 1:19-cv-01979-LPS, 54 in 1:20-cv-00415-LPS, 73 in 1:19-cv-02021-LPS, 102 in 1:20-cv-00445-LPS, 221 in 1:20-md-02930-LPS) STIPULATION and [Proposed] Order Extending Time to Meet and Confer Regarding Depositions. Signed by Judge Leonard P. Stark on 3/15/21. Associated Cases: 1:19-cv-01979-LPS et al. (ntl) |
| Mar 12, 2021 | 74 | Stipulation (12) Docket Text: STIPULATION and [Proposed] Order Extending Deadline to Amend the Pleadings re (45 in 1:19-cv-02021-LPS, 33 in 1:20-cv-00415-LPS, 102 in 1:20-md-02930-LPS, 29 in 1:20-cv-00074-LPS, 78 in 1:19-cv-02053-LPS, 137 in 1:19-cv-01979-LPS, 74 in 1:20-cv-00445-LPS) Scheduling Order,, by Mylan Pharmaceuticals Inc.. (Palapura, Bindu) |
| Mar 11, 2021 | 73 | Stipulation (12) Docket Text: STIPULATION and [Proposed] Order Extending Time to Meet and Confer Regarding Depositions by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| Mar 4, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (213 in 1:20-md-02930-LPS, 206 in 1:19-cv-01979-LPS, 52 in 1:20-cv-00415-LPS, 99 in 1:20-cv-00445-LPS, 71 in 1:19-cv-02021-LPS, 119 in 1:19-cv-02053-LPS, 49 in 1:20-cv-00074-LPS) STIPULATION TO EXTEND TIME for the substantial completion of document production to April 14, 2021 filed by Biocon Limited, Biocon Pharma, Inc., Alkem Laboratories Ltd., Biocon Pharma Limited, Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc. Signed by Judge Leonard P. Stark on 3/3/21. Associated Cases: 1:19-cv-01979-LPS et al. (ntl) |
| Mar 4, 2021 | 72 | Notice of Service (14) Docket Text: NOTICE OF SERVICE of (1) Novartiss Opening Claim Construction Brief and (2) Declaration of Alexander M. Klibanov filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Mar 1, 2021 | 71 | Stipulation to EXTEND Time (12) Docket Text: STIPULATION TO EXTEND TIME for the substantial completion of document production to April 14, 2021 - filed by Alkem Laboratories Ltd., Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc., Biocon Limited, Biocon Pharma Limited, Biocon Pharma, Inc.. (Dorsney, Kenneth) |
| Feb 17, 2021 | 69 | Claim Construction Chart (23) Docket Text: CLAIM Construction Chart by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Feb 17, 2021 | 70 | Main Document (15) Docket Text: APPENDIX re (96 in 1:20-cv-00445-LPS, 117 in 1:19-cv-02053-LPS, 199 in 1:19-cv-01979-LPS, 69 in 1:19-cv-02021-LPS, 50 in 1:20-cv-00415-LPS, 205 in 1:20-md-02930-LPS, 47 in 1:20-cv-00074-LPS) Claim Construction Chart by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit 1-17, # (2) Exhibit 18-25, # (3) Exhibit 26-36)(Silver, Daniel) |
| Feb 17, 2021 | 70 | Exhibit 1-17 (163) |
| Feb 17, 2021 | 70 | Exhibit 18-25 (146) |
| Feb 17, 2021 | 70 | Exhibit 26-36 (92) |
| Feb 16, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (68 in 1:19-cv-02021-LPS, 196 in 1:19-cv-01979-LPS, 115 in 1:19-cv-02053-LPS, 201 in 1:20-md-02930-LPS, 49 in 1:20-cv-00415-LPS, 95 in 1:20-cv-00445-LPS, 46 in 1:20-cv-00074-LPS) STIPULATION TO EXTEND TIME the Deadline for the Parties to Submit a Joint Claim Construction Chart to February 17, 2021 filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 2/16/21. Associated Cases: 1:19-cv-01979-LPS et al. (ntl) |
| Feb 12, 2021 | 68 | Stipulation to EXTEND Time (11) Docket Text: STIPULATION TO EXTEND TIME the Deadline for the Parties to Submit a Joint Claim Construction Chart to February 17, 2021 - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Feb 1, 2021 | 67 | Notice of Service (15) Docket Text: NOTICE OF SERVICE of Novartis's Rebuttal Proposed Constructions of Claim Terms and Intrinsic Evidence filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Jan 29, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (198 in 1:20-md-02930-LPS) (44 in 1:20-cv-00074-LPS, 92 in 1:20-cv-00445-LPS, 47 in 1:20-cv-00415-LPS, 113 in 1:19-cv-02053-LPS, 66 in 1:19-cv-02021-LPS, 194 in 1:19-cv-01979-LPS) STIPULATION TO EXTEND TIME for completion of production of documents to March 15, 2021 filed by Macleods Pharmaceuticals Ltd., Macleods Pharma USA, Inc. Signed by Judge Leonard P. Stark on 1/28/21. Associated Cases: 1:20-md-02930-LPS et al. (ntl) |
| Jan 27, 2021 | 66 | Stipulation to EXTEND Time (12) Docket Text: STIPULATION TO EXTEND TIME for completion of production of documents to March 15, 2021 - filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd.. (Seaman, John) |
| Jan 22, 2021 | 65 | Notice of Service (14) Docket Text: NOTICE OF SERVICE of (1) Novartis's First Supplemental Objections and Responses to Defendants' First Set of Interrogatories (Nos. 1-7) and (2) Novartis's First Set of Common Interrogatories to Defendants filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Jan 15, 2021 | 64 | Notice of Service (5) Docket Text: NOTICE OF SERVICE of Defendant Crystal Pharmaceutical (Suzhou) Co., Ltd.s First Set of Individual Interrogatories (Nos. 1-3) to Plaintiff Novartis Pharmaceuticals Corporation filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) |
| Jan 9, 2021 | 63 | Notice of Service (6) Docket Text: NOTICE OF SERVICE of Defendants Preliminary Claim Constructions and Supporting Evidence filed by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc., Dr. Reddys Laboratories, Inc..(Stamoulis, Stamatios) |
| Dec 7, 2020 | 62 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Defendants' Joint Invalidity Contentions filed by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc.,, Torrent Pharmaceuticals Ltd., Dr. Reddys Laboratories, Inc., Hetero USA Inc..(Ormerod, Eve) |
| Dec 2, 2020 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Corey Weinstein for Macleods Pharma USA, Inc., for Macleods Pharmaceuticals Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (myr) |
| Dec 1, 2020 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [61] MOTION for Pro Hac Vice Appearance of Attorney Corey Weinstein filed by Macleods Pharmaceuticals Ltd., Macleods Pharma USA, Inc. Signed by Judge Leonard P. Stark on 12/1/20. (ntl) |
| Nov 25, 2020 | 60 | Notice (Other) (1) Docket Text: NOTICE of Withdrawal of Appearance of Laura R. Braden by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd. re Add Attorneys Pro Hac Vice, SO ORDERED (Seaman, John) |
| Nov 25, 2020 | 61 | Main Document (2) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Corey Weinstein - filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd.. (Attachments: # (1) Certification of Corey Weinstein, Esq., # (2) Text of Proposed Order)(Seaman, John) |
| Nov 25, 2020 | 61 | Certification of Corey Weinstein, Esq. (1) |
| Nov 25, 2020 | 61 | Text of Proposed Order (1) |
| Nov 19, 2020 | 58 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Macleods Pharmaceuticals Ltd. and Macleods Pharma USA, Inc.'s Objections and Responses to Novartis's Second Set of Interrogatories (Nos. 3-5) filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Seaman, John) |
| Nov 19, 2020 | 59 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Alembic's Objections and Responses to Plaintiff's Second Set of Interrogatories (Nos. 3-5) filed by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc..(Ormerod, Eve) |
| Nov 16, 2020 | 57 | Notice of Service (13) Docket Text: NOTICE OF SERVICE of Novartis's Objections and Responses to Defendants' First Set of Interrogatories (Nos. 1-7) filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Nov 4, 2020 | 56 | Notice of Substitution of Counsel (2) Docket Text: NOTICE OF SUBSTITUTION OF COUNSEL re Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc.: Entry of appearance of attorney Eve H. Ormerod. Attorney Helena C. Rychlicki terminated. (Ormerod, Eve) |
| Oct 22, 2020 | 54 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Macleods Pharmaceuticals Ltd. and Macleods Pharma USA, Inc.'s Objections and Responses to Novartis's First Set of Interrogatories (Nos. 1-2) filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Seaman, John) |
| Oct 22, 2020 | 55 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Alembic Pharmaceuticals Limited's and Alembic Pharmaceuticals, Inc.'s Response to Novartis's First Set of Interrogatories (Nos. 1-2) filed by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc..(Rychlicki, Helena) |
| Oct 21, 2020 | 53 | Notice of Service (20) Docket Text: NOTICE OF SERVICE of (1) Novartiss Second Set of Interrogatories to Defendants (Nos. 3-5) and (2) Plaintiffs Initial Infringement Chart Against Defendants filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Oct 20, 2020 | 52 | Notice of Service (14) Docket Text: NOTICE OF SERVICE of Novartis's Objections and Responses to Defendants' First Set of Joint Requests for the Production of Documents and Things (Nos. 1-108) filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Oct 15, 2020 | 51 | Notice of Service (5) Docket Text: NOTICE OF SERVICE of Defendants First Set of Interrogatories (Nos. 1-7) to Plaintiff Novartis Pharmaceuticals Corporation filed by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc., Dr. Reddys Laboratories, Inc..(Stamoulis, Stamatios) |
| Oct 2, 2020 | 49 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of (i) Macleods Pharmaceuticals Ltd. and Macleods Pharma USA, Inc.'s Objections and Responses to Novartis's Second Set of Requests for Production (Nos. 15-61) and (ii) Macleods Pharmaceuticals Ltd. and Macleods Pharma USA, Inc.'s Highly Confidential Objections and Responses to Novartis's Third Set of Requests for Production (Nos. 62-74) filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Seaman, John) |
| Oct 2, 2020 | 50 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Alembic Pharmaceuticals Limited's and Alembic Pharmaceuticals, Inc.'s Response to Novartis's Second Set of Requests for the Production of Documents and Things (Nos. 15-61) and Alembic Pharmaceuticals Limited's and Alembic Pharmaceuticals, Inc.'s Response to Novartis's Third Set of Requests for the Production of Documents and Things (Nos. 62-74) filed by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc..(Rychlicki, Helena) |
| Sep 28, 2020 | 47 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Macleods Pharmaceuticals Ltd. and Macleods Pharma USA, Inc.'s Objections and Responses to Novartis's First Set of Requests for Production (Nos. 1-14) filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Seaman, John) |
| Sep 28, 2020 | 48 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Alembic Pharmaceuticals Limiteds and Alembic Pharmaceuticals, Inc.s Response to Novartiss First Set of Requests for the Production of Documents and Things (Nos. 1-14) filed by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc..(Rychlicki, Helena) |
| Sep 22, 2020 | 46 | Notice of Service (17) Docket Text: NOTICE OF SERVICE of Novartis's First Set of Interrogatories to Defendants (Nos. 1-2) filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Sep 18, 2020 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (24 in 1:20-cv-00074-LPS, 80 in 1:20-md-02930-LPS, 67 in 1:19-cv-02053-LPS, 40 in 1:19-cv-02021-LPS, 68 in 1:20-cv-00445-LPS, 122 in 1:19-cv-01979-LPS, 26 in 1:20-cv-00415-LPS) STIPULATED PROTECTIVE ORDER. Signed by Judge Leonard P. Stark on 9/14/20. Associated Cases: 1:19-cv-01979-LPS et al. (ntl) |
| Sep 18, 2020 | 45 | Scheduling Order (24) Docket Text: SCHEDULING ORDER: Case referred to the Magistrate Judge for the purpose of exploring ADR. Fact Discovery completed by 10/20/2021. Status Report due by 11/3/2021. Joint Claim Construction Brief due by 5/21/2021. A Markman Hearing is set for 6/7/2021 at 12:30 PM in Courtroom 6B before Judge Leonard P. Stark. A Final Pretrial Conference is set for 8/26/2022 at 09:00 AM in Courtroom 6B before Judge Leonard P. Stark. A 12-day Bench Trial is set for 9/8/2022 at 08:30 AM in Courtroom 6B before Judge Leonard P. Stark. Signed by Judge Leonard P. Stark on 9/14/20. Associated Cases: 1:19-cv-01979-LPS et al. (ntl) |
| Sep 17, 2020 | 44 | Notice of Service (5) Docket Text: NOTICE OF SERVICE of Defendants' First Set of Joint Requests for the Production of Documents and Things (Nos. 1-108) to Plaintiff Novartis Pharmaceuticals Corporation filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) |
| Sep 11, 2020 | 43 | Proposed Order (26) Docket Text: PROPOSED ORDER Scheduling by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Sep 9, 2020 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (42 in 1:19-cv-02021-LPS, 71 in 1:20-cv-00445-LPS, 73 in 1:19-cv-02053-LPS, 132 in 1:19-cv-01979-LPS, 26 in 1:20-cv-00074-LPS, 29 in 1:20-cv-00415-LPS, 95 in 1:20-md-02930-LPS) STIPULATION TO EXTEND TIME the Deadline for the Parties to Submit a Revised Proposed Scheduling Order to September 11, 2020 filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 9/8/20. Associated Cases: 1:20-md-02930-LPS et al. (ntl) |
| Sep 4, 2020 | 42 | Stipulation to EXTEND Time (10) Docket Text: STIPULATION TO EXTEND TIME the Deadline for the Parties to Submit a Revised Proposed Scheduling Order to September 11, 2020 - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Sep 3, 2020 | 41 | Notice of Service (19) Docket Text: NOTICE OF SERVICE of (1) Novartiss Second Set of Requests to Defendants for the Production of Documents and Things ; and (2) Novartiss Third Set of Requests to Defendants for the Production of Documents and Things filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Aug 31, 2020 | 39 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendants Macleods Pharmaceuticals Ltd. and Macleods Pharma USA, Inc.'s Notice Pursuant to August 24, 2020 Order filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Seaman, John) |
| Aug 31, 2020 | 40 | Proposed Order (30) Docket Text: PROPOSED ORDER Stipulated Protective Order by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Aug 28, 2020 | 38 | Notice of Service (19) Docket Text: NOTICE OF SERVICE of Novartis's First Set of Requests to Defendants for the Production of Documents and Things filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Aug 27, 2020 | 37 | Transcript (66) Docket Text: Official Transcript of Telephone Conference held on August 24, 2020 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, e-mail: gaffigan@verizon.net. Transcript may be viewed at the court public terminal or ordered/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 9/17/2020. Redacted Transcript Deadline set for 9/28/2020. Release of Transcript Restriction set for 11/25/2020. (bpg) |
| Aug 25, 2020 | N/A | Order (0) Docket Text: ORAL ORDER: For the reasons stated during the teleconference on August 24, 2020, IT IS HEREBY ORDERED THAT a revised version of the proposed protective order is due on August 31, 2020, and a revised version of the proposed scheduling order is due on September 4, 2020, both incorporating the dates and decisions the Court announced during the hearing, including that the bench trial (not to exceed 12 days) will be held between September 8 and 23, 2022. ORDERED by Judge Leonard P. Stark on 8/25/20. Associated Cases: 1:19-cv-01979-LPS et al. (ntl) |
| Aug 24, 2020 | N/A | Telephone Conference (0) Docket Text: Minute Entry for proceedings held before Judge Leonard P. Stark - Telephone Conference held on 8/24/2020. (Court Reporter B. Gaffigan.) Associated Cases: 1:19-cv-01979-LPS et al. (ntl) |
| Aug 20, 2020 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (61 in 1:19-cv-02053-LPS, 69 in 1:20-md-02930-LPS, 63 in 1:20-cv-00445-LPS, 19 in 1:20-cv-00074-LPS, 112 in 1:19-cv-01979-LPS, 21 in 1:20-cv-00415-LPS, 33 in 1:19-cv-02021-LPS) STIPULATION TO EXTEND TIME for parties to submit a proposed scheduling order, proposed protective order, and letters regarding the disputed provisions to August 18, 2020 at 12:00 p.m. EST filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 8/20/20. Associated Cases: 1:19-cv-01979-LPS et al. (ntl) |
| Aug 18, 2020 | 34 | Main Document (10) Docket Text: Joint Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Regarding Disputed Provisions of Proposed Scheduling Order. (Attachments: # (1) Exhibit A-K, # (2) Text of Proposed Order [Reflecting Parties' Disagreements])(Silver, Daniel) |
| Aug 18, 2020 | 34 | Exhibit A-K (224) |
| Aug 18, 2020 | 34 | Text of Proposed Order [Reflecting Parties' Disagreements] (37) |
| Aug 18, 2020 | 35 | Main Document (9) Docket Text: Joint Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Disputed Provisions of Proposed Protective Order. (Attachments: # (1) Exhibit 1-2, # (2) Text of Proposed Order [Reflecting Parties' Disagreements])(Silver, Daniel) |
| Aug 18, 2020 | 35 | Exhibit 1-2 (16) |
| Aug 18, 2020 | 35 | Text of Proposed Order [Reflecting Parties' Disagreements] (49) |
| Aug 17, 2020 | 33 | Stipulation to EXTEND Time (11) Docket Text: STIPULATION TO EXTEND TIME for parties to submit a proposed scheduling order, proposed protective order, and letters regarding the disputed provisions to August 18, 2020 at 12:00 p.m. EST - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Jul 29, 2020 | N/A | Order Setting Teleconference (0) Docket Text: ORAL ORDER: IT IS HEREBY ORDERED that a Scheduling and Discovery Telephone Conference is set for August 24, 2020 at 9:30 AM. The parties can access the teleconference by dialing 877-336-1829 and using the access code 1408971. The parties shall confer and submit a proposed schedule, proposed protective order, and letter(s) regarding the disputed provisions, all by no later than August 17. ORDERED by Judge Leonard P. Stark on 7/29/20. Associated Cases: 1:20-md-02930-LPS, 1:19-cv-01979-LPS, 1:19-cv-02021-LPS, 1:19-cv-02053-LPS, 1:20-cv-00445-LPS (ntl) |
| Jul 27, 2020 | 31 | Notice of Service (13) Docket Text: NOTICE OF SERVICE of (1) Plaintiffs Rule 26(A)(1) Initial Disclosures; (2) Plaintiffs Initial Paragraph 3 Disclosures Regarding Electronic Systems Information; and (3) Plaintiffs Identification of Asserted patents and Accused Products pursuant to Paragraph 4(a) of the Delaware Default Standard for Discovery filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Jul 8, 2020 | 30 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of (i) Defendants Macleods Pharmaceuticals Ltd. and Macleods Pharma USA, Inc.'s Rule 26(a)(1) Initial Disclosures; and (ii) Defendants Macleods Pharmaceuticals Ltd. and Macleods Pharma USA, Inc.'s Disclosures Pursuant to Paragraph 3 of the Default Standard for Discovery filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Seaman, John) |
| May 27, 2020 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Laura R. Braden for Macleods Pharma USA, Inc., for Macleods Pharmaceuticals Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (myr) |
| May 27, 2020 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney A. Neal Seth for Macleods Pharma USA, Inc.,for Macleods Pharmaceuticals Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (myr) |
| May 7, 2020 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [29] MOTION for Pro Hac Vice Appearance of Attorney Laura R. Braden, Esq. and A. Neal Seth, Esq. filed by Macleods Pharmaceuticals Ltd., Macleods Pharma USA, Inc. Signed by Judge Leonard P. Stark on 5/7/20. (ntl) |
| May 6, 2020 | 29 | Main Document (2) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Laura R. Braden, Esq. and A. Neal Seth, Esq. - filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd.. (Attachments: # (1) Certification of Laura R. Braden, # (2) Certification of A. Neal Seth, # (3) Text of Proposed Order)(Seaman, John) |
| May 6, 2020 | 29 | Certification of Laura R. Braden (1) |
| May 6, 2020 | 29 | Certification of A. Neal Seth (1) |
| May 6, 2020 | 29 | Text of Proposed Order (1) |
| Mar 31, 2020 | N/A | CORRECTING ENTRY: (0) Docket Text: CORRECTING ENTRY: Case from West VA was inadvertently opened as 20-MD-445. The proper case number is 20-CV-445. Associated Cases: 1:20-cv-00445-LPS et al.(rwc) |
| Mar 30, 2020 | 28 | Remark - MDL Notice to Counsel (1) Docket Text: NOTICE TO COUNSEL: MDL No. 1:20-md-2930 has been opened and assigned to the Honorable Leonard P. Stark. Attorneys of record who will be electronically filing documents may use the attached form to register for a CM/ECF login and password or they may continue to go through their Local Counsel. Please see the docket for further entries. Associated Cases: 1:20-md-02930-LPS, 1:19-cv-01979-LPS, 1:19-cv-02021-LPS, 1:19-cv-02053-LPS(rwc) |
| Mar 27, 2020 | N/A | Remark - MDL Member (0) Docket Text: NOTICE: Documents relating to all actions should be filed on the master docket sheet (20-MD-2930) AND on the docket sheet of each individual action. Documents relating to two or more, but not all, individual actions should be filed on the master docket sheet, and on the docket sheet of each affected individual action. Documents affecting a single individual action should be filed on the docket sheet of that action and on the master docket sheet. Associated Cases: 1:20-md-02930-LPS, 1:19-cv-01979-LPS, 1:19-cv-02021-LPS, 1:19-cv-02053-LPS(rwc) |
| Mar 27, 2020 | 27 | Order (4) Docket Text: CERTIFIED TRANSFER ORDER re: 20-MD-2930 - signed 3/27/20 by Clerk, MDL Panel. (rwc) |
| Mar 3, 2020 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Frank D. Rodriguez for Alembic Pharmaceuticals Limited,Frank D. Rodriguez for Alembic Pharmaceuticals, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mal) |
| Mar 2, 2020 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Amit Singhai for Alembic Pharmaceuticals Limited, and Alembic Pharmaceuticals, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:19-cv-02021-LPS, 1:20-cv-00074-LPS(sam) |
| Feb 28, 2020 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Jared L. Stringham, and Nicholas N. Kallas for Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:19-cv-01979-LPS, 1:19-cv-02021-LPS, 1:19-cv-02053-LPS, 1:20-cv-00074-LPS(sam) |
| Feb 28, 2020 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [24] MOTION for Pro Hac Vice Appearance of Attorney Frank D. Rodriguez filed by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc., [25] MOTION for Pro Hac Vice Appearance of Attorney Amit Singhai filed by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc. Signed by Judge Leonard P. Stark on 2/28/20. (ntl) |
| Feb 27, 2020 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (63 in 1:19-cv-01979-LPS, 43 in 1:19-cv-02053-LPS, 23 in 1:19-cv-02021-LPS, 10 in 1:20-cv-00074-LPS) MOTION for Pro Hac Vice Appearance of Attorney Nichols N. Kallas, Christina Schwarz, and Jared L. Stringham filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 2/27/20. Associated Cases: 1:19-cv-01979-LPS, 1:19-cv-02021-LPS, 1:19-cv-02053-LPS, 1:20-cv-00074-LPS (ntl) |
| Feb 27, 2020 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Christina Schwarz for Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:19-cv-01979-LPS, 1:19-cv-02021-LPS, 1:19-cv-02053-LPS, 1:20-cv-00074-LPS(kmd) |
| Feb 27, 2020 | 24 | Main Document (2) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Frank D. Rodriguez - filed by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc.. (Attachments: # (1) Certificate of Service)(Rychlicki, Helena) |
| Feb 27, 2020 | 24 | Certificate of Service (1) |
| Feb 27, 2020 | 25 | Main Document (2) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Amit Singhai - filed by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc.. (Attachments: # (1) Certificate of Service)(Rychlicki, Helena) |
| Feb 27, 2020 | 25 | Certificate of Service (1) |
| Feb 27, 2020 | 26 | Answer to Counterclaim (12) Docket Text: ANSWER to [19] Answer to Complaint, Counterclaim / Plaintiff's Answer to Alembic Pharmaceuticals, Inc.'s Counterclaims by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Feb 25, 2020 | 23 | Main Document (3) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Nichols N. Kallas, Christina Schwarz, and Jared L. Stringham - filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Certifications for Nichols N. Kallas, Christina Schwarz, and Jared L. Stringham)(Silver, Daniel) |
| Feb 25, 2020 | 23 | Certifications for Nichols N. Kallas, Christina Schwarz, and Jared L. Stringham (3) |
| Feb 19, 2020 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [22] STIPULATION and Proposed Order Dismissing the Natco Defendants -- Party Natco Pharma Limited and Natco Pharma, Inc. terminated. Attorney Kelly E. Farnan terminated. Signed by Judge Leonard P. Stark on 2/19/20. (ntl) |
| Feb 11, 2020 | 22 | Stipulation (2) Docket Text: STIPULATION and Proposed Order Dismissing the Natco Defendants by Natco Pharma Limited, Natco Pharma, Inc.. (Farnan, Kelly) |
| Feb 7, 2020 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [21] STIPULATION TO EXTEND TIME for Defendants Natco Pharma Limited and Natco Pharma, Inc. to move, answer, or otherwise respond to the Complaint to February 13, 2020 filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 2/7/20. (ntl) |
| Feb 6, 2020 | 18 | Main Document (1) Docket Text: NOTICE of Appearance by Helena C. Rychlicki on behalf of Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc. (Attachments: # (1) Certificate of Service)(Rychlicki, Helena) |
| Feb 6, 2020 | 18 | Certificate of Service (1) |
| Feb 6, 2020 | 19 | Main Document (27) Docket Text: ANSWER to [1] Complaint, , COUNTERCLAIM against Novartis Pharmaceuticals Corporation by Alembic Pharmaceuticals, Inc., Alembic Pharmaceuticals Limited. (Attachments: # (1) Certificate of Service)(Rychlicki, Helena) |
| Feb 6, 2020 | 19 | Certificate of Service (1) |
| Feb 6, 2020 | 20 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying filed by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc.. (Rychlicki, Helena) |
| Feb 6, 2020 | 21 | Stipulation to EXTEND Time (2) Docket Text: STIPULATION TO EXTEND TIME for Defendants Natco Pharma Limited and Natco Pharma, Inc. to move, answer, or otherwise respond to the Complaint to February 13, 2020 - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Jan 28, 2020 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [16] STIPULATION and Order Dismissing Alembic Global Holding SA Without Prejudice and Amending Caption to Reflect Same filed by Novartis Pharmaceuticals Corporation -- Party Alembic Global Holding SA terminated. Signed by Judge Leonard P. Stark on 1/28/20. (ntl) |
| Jan 28, 2020 | 17 | Answer to Counterclaim (9) Docket Text: ANSWER to [14] Answer to Complaint,, Counterclaim, by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Jan 24, 2020 | 16 | Stipulation (6) Docket Text: STIPULATION and Order Dismissing Alembic Global Holding SA Without Prejudice and Amending Caption to Reflect Same by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Jan 8, 2020 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [12] STIPULATION TO EXTEND TIME Defendants Alembic Pharmaceuticals Limited, Alembic Global Holding SA, and Alembic Pharmaceuticals, Inc. Deadline to Answer, Move, or Otherwise Respond to Complaint to February 6, 2020 filed by Novartis Pharmaceuticals Corporation, [13] STIPULATION TO EXTEND TIME to Move, Answer or Otherwise Respond to the Complaint to February 6, 2020 filed by Natco Pharma, Inc., Natco Pharma Limited. Signed by Judge Leonard P. Stark on 1/8/2020. (ntl) |
| Jan 7, 2020 | 14 | Answer to Complaint (26) Docket Text: ANSWER to [1] Complaint, /Defendants Macleods Pharmaceuticals Ltd. and Macleods Pharma USA, Inc.'s Answer and Counterclaims, COUNTERCLAIM against Novartis Pharmaceuticals Corporation by Macleods Pharmaceuticals Ltd., Macleods Pharma USA, Inc..(Seaman, John) |
| Jan 7, 2020 | 15 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd.. (Seaman, John) |
| Jan 6, 2020 | 12 | Stipulation to EXTEND Time (2) Docket Text: STIPULATION TO EXTEND TIME Defendants Alembic Pharmaceuticals Limited, Alembic Global Holding SA, and Alembic Pharmaceuticals, Inc. Deadline to Answer, Move, or Otherwise Respond to Complaint to February 6, 2020 - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Jan 6, 2020 | 13 | Stipulation to EXTEND Time (2) Docket Text: STIPULATION TO EXTEND TIME to Move, Answer or Otherwise Respond to the Complaint to February 6, 2020 - filed by Natco Pharma Limited, Natco Pharma, Inc.. (Farnan, Kelly) |
| Dec 12, 2019 | 6 | Waiver of Service Executed (1) Docket Text: WAIVER OF SERVICE returned executed by Novartis Pharmaceuticals Corporation: For Alembic Pharmaceuticals, Inc. waiver sent on 11/8/2019, answer due 1/7/2020. (Silver, Daniel) |
| Dec 12, 2019 | 7 | Waiver of Service Executed (1) Docket Text: WAIVER OF SERVICE returned executed by Novartis Pharmaceuticals Corporation: For Alembic Pharmaceuticals Limited waiver sent on 11/8/2019, answer due 1/7/2020. (Silver, Daniel) |
| Dec 12, 2019 | 8 | Waiver of Service Executed (1) Docket Text: WAIVER OF SERVICE returned executed by Novartis Pharmaceuticals Corporation: For Macleods Pharma USA, Inc. waiver sent on 11/8/2019, answer due 1/7/2020. (Silver, Daniel) |
| Dec 12, 2019 | 9 | Waiver of Service Executed (1) Docket Text: WAIVER OF SERVICE returned executed by Novartis Pharmaceuticals Corporation: For Macleods Pharmaceuticals Ltd. waiver sent on 11/8/2019, answer due 1/7/2020. (Silver, Daniel) |
| Dec 12, 2019 | 10 | Waiver of Service Executed (1) Docket Text: WAIVER OF SERVICE returned executed by Novartis Pharmaceuticals Corporation: For Natco Pharma, Inc. waiver sent on 11/8/2019, answer due 1/7/2020. (Silver, Daniel) |
| Dec 12, 2019 | 11 | Waiver of Service Executed (1) Docket Text: WAIVER OF SERVICE returned executed by Novartis Pharmaceuticals Corporation: For Natco Pharma Limited waiver sent on 11/8/2019, answer due 1/7/2020. (Silver, Daniel) |
| Oct 30, 2019 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Assigned to Judge Leonard P. Stark. Please include the initials of the Judge (LPS) after the case number on all documents filed. (rjb) |
| Oct 24, 2019 | N/A | No Summons Issued (0) Docket Text: No Summons Issued. (kmd) |
| Oct 24, 2019 | 1 | Main Document (31) Docket Text: COMPLAINT filed against Alembic Global Holding SA, Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc., Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd., Natco Pharma Limited, Natco Pharma, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-2763203.) - filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibits A-D, # (2) Civil Cover Sheet)(kmd) |
| Oct 24, 2019 | 1 | Exhibit A-D (63) |
| Oct 24, 2019 | 1 | Civil Cover Sheet (1) |
| Oct 24, 2019 | 2 | Magistrate Consent Forms (3) Docket Text: Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (kmd) |
| Oct 24, 2019 | 3 | ANDA Form (3) Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 9/11/2019. Date of Expiration of Patent: see attached.Thirty Month Stay Deadline: 7/7/2023. (kmd) |
| Oct 24, 2019 | 4 | Patent/Trademark Report to Commissioner (2) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,101,659; 8,796,331; 8,877,938; 9,388,134. (kmd) |
| Oct 24, 2019 | 5 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novartis AG for Novartis Pharmaceuticals Corporation filed by Novartis Pharmaceuticals Corporation. (kmd) |
| Oct 24, 2019 | 1 | Complaint* (1) |
